Synthetic HIV-1 matrix protein p17-based AT20-KLH therapeutic immunization in HIV-1-infected patients receiving antiretroviral treatment: A phase I safety and immunogenicity study

Abstract

BACKGROUND Therapeutic vaccination is a promising novel approach to treat HIV-1 infected people by boosting or redirecting immune system to neutralize critical HIV-1 antigens whose biological effects are relevant in the context of viral pathogenesis. With the aim to induce neutralizing antibodies to the matrix protein p17 we have developed a peptide-based… (More)
DOI: 10.1016/j.vaccine.2013.12.051

Topics

Cite this paper

@inproceedings{Caruso2014SyntheticHM, title={Synthetic HIV-1 matrix protein p17-based AT20-KLH therapeutic immunization in HIV-1-infected patients receiving antiretroviral treatment: A phase I safety and immunogenicity study}, author={Arnaldo Caruso and Marialuisa Iaria and Francesca Caccuri and Cinzia Giagulli and Simona Fiorentini}, booktitle={Vaccine}, year={2014} }